Biology:Antimicrobial peptides

From HandWiki
Short description: Class of peptides that have antimicrobial activity
Various structures of antimicrobial peptides

Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antimicrobials which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria,[1] enveloped viruses, fungi and even transformed or cancerous cells.[2] Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

Structure

Antimicrobial peptides from animals, plants and fungi organised by their secondary structure content. Circle size indicates overall molecular weight of each peptide.

Antimicrobial peptides are a unique and diverse group of molecules, which are divided into subgroups on the basis of their amino acid composition and structure.[3] Antimicrobial peptides are generally between 12 and 50 amino acids. These peptides include two or more positively charged residues provided by arginine, lysine or, in acidic environments, histidine, and a large proportion (generally >50%) of hydrophobic residues.[4][5][6] The secondary structures of these molecules follow 4 themes, including i) α-helical, ii) β-stranded due to the presence of 2 or more disulfide bonds, iii) β-hairpin or loop due to the presence of a single disulfide bond and/or cyclization of the peptide chain, and iv) extended.[7] Many of these peptides are unstructured in free solution, and fold into their final configuration upon partitioning into biological membranes. The peptides contain hydrophilic amino acid residues aligned along one side and hydrophobic amino acid residues aligned along the opposite side of a helical molecule.[3] This amphipathicity of the antimicrobial peptides allows them to partition into the membrane lipid bilayer. The ability to associate with membranes is a definitive feature of antimicrobial peptides,[8][9] although membrane permeabilization is not necessary. These peptides have a variety of antimicrobial activities ranging from membrane permeabilization to action on a range of cytoplasmic targets.[citation needed]

Type characteristic AMPs
Anionic peptides rich in glutamic and aspartic acids Maximin H5 from amphibians, dermcidin from humans
Linear cationic α-helical peptides lack in cysteine Cecropins, andropin, moricin, ceratotoxin and melittin from insects, Magainin, dermaseptin, bombinin, brevinin-1, esculentins and buforin II from amphibians, CAP18 from rabbits, LL37 from humans
Cationic peptide enriched for specific amino acid rich in proline, arginine, phenylalanine, glycine, tryptophan abaecin and drosocin, apidaecin, diptericin, and attacin from insects, prophenin from pigs, indolicidin from cattle.
Anionic/cationic peptides forming disulfide bonds contain 1~3 disulfide bond
  • 1 bond: brevinins;
  • 2 bonds: protegrin from pig, tachyplesins from horseshoe crabs;
  • 3 bonds: defensins from humans;
  • more than 3: drosomycin in fruit flies

Activities

The modes of action by Antimicrobial peptides

The modes of action by which antimicrobial peptides kill microbes are varied,[10] and may differ for different bacterial species.[11] Some antimicrobial peptides kill both bacteria and fungi, e.g., psoriasin kills E. coli and several filamentous fungi.[12] The cytoplasmic membrane is a frequent target, but peptides may also interfere with DNA and protein synthesis, protein folding, and cell wall synthesis.[10] The initial contact between the peptide and the target organism is electrostatic, as most bacterial surfaces are anionic, or hydrophobic, such as in the antimicrobial peptide Piscidin. Their amino acid composition, amphipathicity, cationic charge and size allow them to attach to and insert into membrane bilayers to form pores by ‘barrel-stave’, ‘carpet’ or ‘toroidal-pore’ mechanisms. Alternately, they may penetrate into the cell to bind intracellular molecules which are crucial to cell living.[13] Intracellular binding models includes inhibition of cell wall synthesis, alteration of the cytoplasmic membrane, activation of autolysin, inhibition of DNA, RNA, and protein synthesis, and inhibition of certain enzymes. In many cases, the exact mechanism of killing is not known. One emerging technique for the study of such mechanisms is dual polarisation interferometry.[14][15] In contrast to many conventional antibiotics these peptides appear to be bactericidal[2] instead of bacteriostatic. In general the antimicrobial activity of these peptides is determined by measuring the minimal inhibitory concentration (MIC), which is the lowest concentration of drug that inhibits bacterial growth.[16]

AMPs can possess multiple activities including anti-gram-positive bacterial, anti-gram-negative bacterial, anti-fungal, anti-viral, anti-parasitic, and anti cancer activities. A big AMP functional analysis indicates that among all AMP activities, amphipathicity and charge, two major properties of AMPs, best distinguish between AMPs with and without anti-gram-negative bacterial activities.[17] This implies that being AMPs with anti-gram-negative bacterial activities may prefer or even require strong amphipathicity and net positive charge.[citation needed]

Immunomodulation

In addition to killing bacteria directly they have been demonstrated to have a number of immunomodulatory functions that may be involved in the clearance of infection, including the ability to alter host gene expression, act as chemokines and/or induce chemokine production, inhibiting lipopolysaccharide induced pro-inflammatory cytokine production, promoting wound healing, and modulating the responses of dendritic cells and cells of the adaptive immune response. Animal models indicate that host defense peptides are crucial for both prevention and clearance of infection. It appears as though many peptides initially isolated as and termed "antimicrobial peptides" have been shown to have more significant alternative functions in vivo (e.g. hepcidin[18]). Dusquetide for example is an immunomodulator that acts through p62, a protein involved in toll like receptor based signalling of infection. The peptide is being examined in a Phase III clinical trial by Soligenix (SGNX) to ascertain if it can assist in repair of radiation-induced damage to oral mucosa arising during cancer radiotherapy of the head and neck.[19]

Mechanisms of action

Scanning electron microscopic images (50,000X magnification) displaying the action of an experimental antimicrobial peptide (NN2_0050) on the cell membrane of E. coli (K12 MG1655) [1] ABOVE: Intact cell membranes in the control group. BELOW: Disrupted cell membranes and leakage of bacterial chromosome (green) in the treated group.

Antimicrobial peptides generally have a net positive charge, allowing them to interact with the negatively charged molecules exposed on bacteria and cancer cell surfaces, such as phospholipid phosphatidylserine, O-glycosylated mucins, sialylated gangliosides, and heparin sulfates. The mechanism of action of these peptides varies widely but can be simplified into two categories: membranolytic and non-membranolytic antimicrobial peptides.[20] The disruption of membranes by membranolytic antimicrobial peptides can be described by four models:[20]

  • Barrel-stave model: The barrel-stave model proposes that AMPs interact with the lipid bilayer of the microbial cell membrane to form transmembrane channels or "barrel staves". These channels are thought to disrupt the membrane's integrity, leading to the death of the microbe.
  • Carpet model: The carpet model proposes that AMPs adsorb onto the lipid bilayer of the microbial cell membrane, forming a dense layer that causes the membrane to become permeabilized. This model suggests that the AMP acts as a "carpet" that covers the surface of the cell, preventing the microbe from functioning properly.
  • Toroidal model: The toroidal model proposes that AMPs interact with the lipid bilayer of the microbial cell membrane to form toroidal structures, which are thought to pinch off sections of the membrane and lead to the formation of vesicles. This process is thought to disrupt the membrane's integrity and cause the death of the microbe.
  • Disordered toroidal-pore model: According to this model, the disordered AMPs wrap around the lipid bilayer and create a pore, which disrupts the membrane's integrity and leads to the death of the microbe. Unlike the toroidal model, which suggests that the AMP creates a stable toroidal structure, the disordered toroidal-pore model suggests that the AMP is flexible and does not form a stable toroidal structure. The peptide-lipid pore complex becomes intrinsically disordered, with the orientation of the peptide not well defined.[21]
Schematic representation of the AMPs mechanisms of action when disrupting membranes.[22]

Several methods have been used to determine the mechanisms of antimicrobial peptide activity.[11][13] In particular, solid-state NMR studies have provided an atomic-level resolution explanation of membrane disruption by antimicrobial peptides.[23][24] In more recent years, X-ray crystallography has been used to delineate in atomic detail how the family of plant defensins rupture membranes by identifying key phospholipids in the cell membranes of the pathogen.[25][26] Human defensins have been thought to act through a similar mechanism, targeting cell membrane lipids as part of their function. In fact human beta-defensin 2 have now been shown to kill the pathogenic fungi Candida albicans through interactions with specific phospholipids.[27] From the computational point of view, Molecular Dynamics simulations can provide detailed information about the structure and dynamics of the peptide-membrane interactions, including the orientation, conformation, and insertion of the peptide in the membrane, as well as specific peptide interactions with lipids, ions and solvent.[28]

Methods Applications
Microscopy to visualize the effects of antimicrobial peptides on microbial cells
Atomic emission spectroscopy to detect loss of intracellular potassium (an indication that bacterial membrane integrity has been compromised)
Fluorescent dyes to measure ability of antimicrobial peptides to permeabilize membrane vesicles
Ion channel formation to assess the formation and stability of an antimicrobial-peptide-induced pore
Circular dichroism and orientated circular dichroism to measure the orientation and secondary structure of an antimicrobial peptide bound to a lipid bilayer
Dual polarization interferometry to measure the different mechanisms of antimicrobial peptides
Solid-state NMR spectroscopy to measure the secondary structure, orientation and penetration of antimicrobial peptides into lipid bilayers in the biologically relevant liquid-crystalline state
Neutron and X-ray diffraction to measure the diffraction patterns of peptide-induced pores within membranes in oriented multilayers or liquids
Molecular dynamics simulations to study the molecular behaviour and search for specific peptide-lipid interactions
Mass spectrometry to measure the proteomic response of microorganisms to antimicrobial peptides

Therapeutic research and use

Antimicrobial peptides have been used as therapeutic agents; their use is generally limited to intravenous administration or topical applications due to their short half-lives. As of January 2018 the following antimicrobial peptides were in clinical use:[29]

Activity beyond antibacterial functions

AMPs have been observed having functions other than bacterial and fungal killing. These activities include antiviral effects, but also roles in host defence such as anticancer functions and roles in neurology.[30] This has led to a movement for re-branding AMPs as "Host-defence peptides" to encompass the broad scope of activities AMPs can have.[31]

Anticancer properties

Some cecropins (e.g. cecropin A, and cecropin B) have anticancer properties and are called anticancer peptides (ACPs).[32]:3 Hybrid ACPs based on Cecropin A have been studied for anticancer properties.[32]:7.1 The fruit fly Defensin prevents tumour growth, suspected to bind to tumour cells owing to cell membrane modifications common to most cancer cells, such as phosphatidylserine exposure.[33]

Antibiofilm properties

Cecropin A can destroy planktonic and sessile biofilm-forming uropathogenic E. coli (UPEC) cells, either alone or when combined with the antibiotic nalidixic acid, synergistically clearing infection in vivo (in the insect host Galleria mellonella) without off-target cytotoxicity. The multi-target mechanism of action involves outer membrane permeabilization followed by biofilm disruption triggered by the inhibition of efflux pump activity and interactions with extracellular and intracellular nucleic acids.[34]

Other research

Recently there has been some research to identify potential antimicrobial peptides from prokaryotes,[35] aquatic organisms such as fish,[36][37] and shellfish,[38] and monotremes such as echidnas.[39][40]

Selectivity

In the competition of bacterial cells and host cells with the antimicrobial peptides, antimicrobial peptides will preferentially interact with the bacterial cell to the mammalian cells, which enables them to kill microorganisms without being significantly toxic to mammalian cells.[41]

With regard to cancer cells, they themselves also secrete human antimicrobial peptides including defensin, and in some cases, they are reported to be more resistant than the surrounding normal cells. Therefore, we cannot conclude that selectivity is always high against cancer cells.[42][43]

Factors

There are some factors that are closely related to the selectivity property of antimicrobial peptides, among which the cationic property contributes most. Since the surface of the bacterial membranes is more negatively charged than mammalian cells, antimicrobial peptides will show different affinities towards the bacterial membranes and mammalian cell membranes.[44]

In addition, there are also other factors that will affect the selectivity. It's well known that cholesterol is normally widely distributed in the mammalian cell membranes as a membrane stabilizing agents but absent in bacterial cell membranes; and the presence of these cholesterols will also generally reduce the activities of the antimicrobial peptides, due either to stabilization of the lipid bilayer or to interactions between cholesterol and the peptide. So the cholesterol in mammalian cells will protect the cells from attack by the antimicrobial peptides.[45]

Besides, the transmembrane potential is well known to affect peptide-lipid interactions.[46] There's an inside-negative transmembrane potential existing from the outer leaflet to the inner leaflet of the cell membranes and this inside-negative transmembrane potential will facilitate membrane permeabilization probably by facilitating the insertion of positively charged peptides into membranes. By comparison, the transmembrane potential of bacterial cells is more negative than that of normal mammalian cells, so bacterial membrane will be prone to be attacked by the positively charged antimicrobial peptides.[citation needed]

Similarly, it is also believed that increasing ionic strength,[45] which in general reduces the activity of most antimicrobial peptides, contributes partially to the selectivity of the antimicrobial peptides by weakening the electrostatic interactions required for the initial interaction.

Molecular Basis of Cell Selectivity of Antimicrobial Peptides

Mechanism

The cell membranes of bacteria are rich in acidic phospholipids, such as phosphatidylglycerol and cardiolipin.[41][47]

In contrast, the outer part of the membranes of plants and mammals is mainly composed of lipids without any net charges since most of the lipids with negatively charged headgroups are principally sequestered into the inner leaflet of the plasma membranes.[44] Thus in the case of mammalian cells, the outer surfaces of the membranes are usually made of zwitterionic phosphatidylcholine and sphingomyelin, even though a small portion of the membrane's outer surfaces contain some negatively charged gangliosides. Therefore, the hydrophobic interaction between the hydrophobic face of amphipathic antimicrobial peptides and the zwitterionic phospholipids on the cell surface of mammalian cell membranes plays a major role in the formation of peptide-cell binding.[48]

Dual polarisation interferometry has been used in vitro to study and quantify the association to headgroup, insertion into the bilayer, pore formation and eventual disruption of the membrane.[49][50]

Control

A lot of effort has been put into controlling cell selectivity. For example, attempts have been made to modify and optimize the physicochemical parameters of the peptides to control the selectivities, including net charge, helicity, hydrophobicity per residue (H), hydrophobic moment (μ) and the angle subtended by the positively charged polar helix face (Φ).[46] Other mechanisms like the introduction of D-amino acids and fluorinated amino acids in the hydrophobic phase are believed to break the secondary structure and thus reduce hydrophobic interaction with mammalian cells. It has also been found that Pro→Nlys substitution in Pro-containing β-turn antimicrobial peptides was a promising strategy for the design of new small bacterial cell-selective antimicrobial peptides with intracellular mechanisms of action.[51] It has been suggested that direct attachment of magainin to the substrate surface decreased nonspecific cell binding and led to improved detection limit for bacterial cells such as Salmonella and E. coli.[52]

Bacterial resistance

Bacteria use various resistance strategies to avoid antimicrobial peptide killing.[13]

  • Some microorganisms alter net surface charges. Staphylococcus aureus transports D-alanine from the cytoplasm to the surface teichoic acid which reduces the net negative charge by introducing basic amino groups.[53] S. aureus also modifies its anionic membranes via MprF with L-lysine, increasing the positive net charge.[53]
  • The interaction of antimicrobial peptides with membrane targets can be limited by capsule polysaccharide of Klebsiella pneumoniae.[54]
  • Salmonella species reduce the fluidity of their outer membrane by increasing hydrophobic interactions between an increased number of Lipid A acyl tails by adding myristate to Lipid A with 2-hydroxymyristate and forming hepta-acylated Lipid A by adding palmitate. The increased hydrophobic moment is thought to retard or abolish antimicrobial peptide insertion and pore formation. The residues undergo alteration in membrane proteins. In some Gram-negative bacteria, alteration in the production of outer membrane proteins correlates with resistance to killing by antimicrobial peptides.[55]
  • Non-typeable Hemophilus influenzae transports AMPs into the interior of the cell, where they are degraded. Furthermore, H. influenzae remodels its membranes to make it appear as if the bacterium has already been successfully attacked by AMPs, protecting it from being attacked by more AMPs.[56]
  • ATP-binding cassette transporters import antimicrobial peptides and the resistance-nodulation cell-division efflux pump exports antimicrobial peptides.[57] Both transporters have been associated with antimicrobial peptide resistance
  • Bacteria produce proteolytic enzymes, which may degrade antimicrobial peptides leading to their resistance.[58]
  • Outer membrane vesicles produced by Gram-negative bacteria bind the antimicrobial peptides and sequester them away from the cells, thereby protecting the cells.[59] The outer membrane vesicles are also known to contain various proteases, peptidases and other lytic enzymes, which may have a role in degrading the extracellular peptide and nucleic acid molecules, which if allowed to reach to the bacterial cells may be dangerous for the cells.
  • Cyclic-di-GMP signaling had also been involved in the regulation of antimicrobial peptide resistance in Pseudomonas aeruginosa[60]

While these examples show that resistance can evolve naturally, there is increasing concern that using pharmaceutical copies of antimicrobial peptides can make resistance happen more often and faster. In some cases, resistance to these peptides used as a pharmaceutical to treat medical problems can lead to resistance, not only to the medical application of the peptides, but to the physiological function of those peptides.[61][62]

The ‘Trojan Horse’ approach to solving this problem capitalizes on the innate need for iron by pathogens. “Smuggling” antimicrobials into the pathogen is accomplished by linking them to siderophores for transport. While simple in concept, it has taken many decades of work to accomplish the difficult hurdle of transporting antimicrobials across the cell membranes of pathogens. Lessons learned from the successes and failures of siderophore-conjugate drugs evaluated during the development of novel agents using the ‘Trojan horse’ approach have been reviewed.[63]

Examples

File:AMP Ecc15-19-02-2019.tif Antimicrobial peptides are produced by species across the tree of life, including:

Research has increased in recent years to develop artificially-engineered mimics of antimicrobial peptides such as SNAPPs, in part due to the prohibitive cost of producing naturally-derived AMPs.[68] An example of this is the facially cationic peptide C18G, which was designed from the C-terminal domain of human platelet factor IV.[69] Currently, the most widely used antimicrobial peptide is nisin; being the only FDA approved antimicrobial peptide, it is commonly used as an artificial preservative.[70]

Bioinformatics

Several bioinformatic databases exist to catalogue antimicrobial peptides. The Antimicrobial Peptide Database (APD) is the original and model database for antimicrobial peptides (https://aps.unmc.edu). Based on the APD, other databases have also been built, including ADAM (A Database of Anti-Microbial peptides),[71] BioPD (Biologically active Peptide Database), CAMP (Collection of sequences and structures of antimicrobial peptides),[72] DBAASP (Database of Antimicrobial Activity and Structure of Peptides), DRAMP(Data Repository of Antimicrobial Peptides)Welcome To Dramp Database,[73] and LAMP (Linking AMPs).

The Antimicrobial peptide databases may be divided into two categories on the basis of the source of peptides it contains, as specific databases and general databases. These databases have various tools for antimicrobial peptides analysis and prediction. For example, the APD has a widely used calculation interface. It also provides links to many other tools. CAMP contains AMP prediction, feature calculator, BLAST search, ClustalW, VAST, PRATT, Helical wheel etc. In addition, ADAM allows users to search or browse through AMP sequence-structure relationships. Antimicrobial peptides often encompass a wide range of categories such as antifungal, antibacterial, and antituberculosis peptides.


Tools such as PeptideRanker,[74] PeptideLocator,[75] and AntiMPmod[76][77] allow for the prediction of antimicrobial peptides while others have been developed to predict antifungal and anti-Tuberculosis activities.[78][79]

See also

References

  1. ↑ "Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria". Biochemical Pharmacology 133 (6): 117–138. June 2017. doi:10.1016/j.bcp.2016.09.018. PMID 27663838. 
  2. ↑ 2.0 2.1 "Antimicrobial peptides: premises and promises". International Journal of Antimicrobial Agents 24 (6): 536–547. December 2004. doi:10.1016/j.ijantimicag.2004.09.005. PMID 15555874. 
  3. ↑ 3.0 3.1 "Mechanisms of antimicrobial peptide action and resistance". Pharmacological Reviews 55 (1): 27–55. March 2003. doi:10.1124/pr.55.1.2. PMID 12615953. 
  4. ↑ "Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications". Biotechnology Advances 21 (6): 465–499. September 2003. doi:10.1016/S0734-9750(03)00077-6. PMID 14499150. 
  5. ↑ "Host-defense antimicrobial peptides: importance of structure for activity". Current Pharmaceutical Design 8 (9): 727–742. 2002. doi:10.2174/1381612023395358. PMID 11945168. 
  6. ↑ "LL-37, the only human member of the cathelicidin family of antimicrobial peptides". Biochimica et Biophysica Acta (BBA) - Biomembranes 1758 (9): 1408–1425. September 2006. doi:10.1016/j.bbamem.2006.03.030. PMID 16716248. 
  7. ↑ "The human beta-defensin-3, an antibacterial peptide with multiple biological functions". Biochimica et Biophysica Acta (BBA) - Biomembranes 1758 (9): 1499–1512. September 2006. doi:10.1016/j.bbamem.2006.07.007. PMID 16978580. 
  8. ↑ "Role of membranes in the activities of antimicrobial cationic peptides". FEMS Microbiology Letters 206 (2): 143–149. January 2002. doi:10.1111/j.1574-6968.2002.tb11000.x. PMID 11814654. 
  9. ↑ "Antibacterial activity of linear peptides spanning the carboxy-terminal beta-sheet domain of arthropod defensins". Peptides 27 (11): 2614–2623. November 2006. doi:10.1016/j.peptides.2006.06.010. PMID 16914230. 
  10. ↑ 10.0 10.1 "The expanding scope of antimicrobial peptide structures and their modes of action". Trends in Biotechnology 29 (9): 464–472. September 2011. doi:10.1016/j.tibtech.2011.05.001. PMID 21680034. 
  11. ↑ 11.0 11.1 "Production and evaluation of an antimicrobial peptide-containing wafer formulation for topical application". Current Microbiology 66 (3): 271–278. March 2013. doi:10.1007/s00284-012-0268-3. PMID 23183933. 
  12. ↑ "Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide". Proceedings of the National Academy of Sciences of the United States of America 112 (42): 13039–13044. October 2015. doi:10.1073/pnas.1511197112. PMID 26438863. Bibcode: 2015PNAS..11213039H. 
  13. ↑ 13.0 13.1 13.2 "Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?". Nature Reviews. Microbiology 3 (3): 238–250. March 2005. doi:10.1038/nrmicro1098. PMID 15703760. 
  14. ↑ "Effect of acyl chain structure and bilayer phase state on binding and penetration of a supported lipid bilayer by HPA3". European Biophysics Journal 40 (4): 503–514. April 2011. doi:10.1007/s00249-010-0664-1. PMID 21222117. 
  15. ↑ "Real-time quantitative analysis of lipid disordering by aurein 1.2 during membrane adsorption, destabilisation and lysis". Biochimica et Biophysica Acta (BBA) - Biomembranes 1798 (10): 1977–1986. October 2010. doi:10.1016/j.bbamem.2010.06.023. PMID 20599687. 
  16. ↑ "Susceptibility testing of Antimicrobials in liquid media". Antibiotics in Laboratory Medicine (4th ed.). Baltimore, Md.: Williams and Wilkins. 1996. pp. 52–111. ISBN 978-0-683-05169-8. "National Committee of Laboratory Safety and Standards (NCLSS)" 
  17. ↑ "Large-Scale Analysis of Antimicrobial Activities in Relation to Amphipathicity and Charge Reveals Novel Characterization of Antimicrobial Peptides". Molecules 22 (11): 2037. November 2017. doi:10.3390/molecules22112037. PMID 29165350. 
  18. ↑ "The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis". The Journal of Biological Chemistry 277 (40): 37597–37603. October 2002. doi:10.1074/jbc.M205305200. PMID 12138110. 
  19. ↑ "Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study". Journal of Biotechnology 239: 115–125. December 2016. doi:10.1016/j.jbiotec.2016.10.010. PMID 27746305. 
  20. ↑ 20.0 20.1 "Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance". Frontiers in Microbiology 4 (4): 353. December 2013. doi:10.3389/fmicb.2013.00353. PMID 24367355. 
  21. ↑ Sengupta, Durba; Leontiadou, Hari; Mark, Alan E.; Marrink, Siewert-Jan (2008-10-01). "Toroidal pores formed by antimicrobial peptides show significant disorder" (in en). Biochimica et Biophysica Acta (BBA) - Biomembranes 1778 (10): 2308–2317. doi:10.1016/j.bbamem.2008.06.007. ISSN 0005-2736. PMID 18602889. 
  22. ↑ Balatti, G. E.; Martini, M. F.; Pickholz, M. (2018-07-17). "A coarse-grained approach to studying the interactions of the antimicrobial peptides aurein 1.2 and maculatin 1.1 with POPG/POPE lipid mixtures" (in en). Journal of Molecular Modeling 24 (8): 208. doi:10.1007/s00894-018-3747-z. ISSN 0948-5023. PMID 30019106. https://doi.org/10.1007/s00894-018-3747-z. 
  23. ↑ "MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain". Biophysical Journal 84 (5): 3052–3060. May 2003. doi:10.1016/S0006-3495(03)70031-9. PMID 12719236. Bibcode: 2003BpJ....84.3052H. 
  24. ↑ "Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37". Biochemistry 42 (21): 6545–6558. June 2003. doi:10.1021/bi0273563. PMID 12767238. 
  25. ↑ "X-ray structure of a carpet-like antimicrobial defensin-phospholipid membrane disruption complex" (in En). Nature Communications 9 (1): 1962. May 2018. doi:10.1038/s41467-018-04434-y. PMID 29773800. Bibcode: 2018NatCo...9.1962J. 
  26. ↑ "Phosphoinositide-mediated oligomerization of a defensin induces cell lysis". eLife 3: e01808. April 2014. doi:10.7554/elife.01808. PMID 24692446. 
  27. ↑ "Human β-defensin 2 kills Candida albicans through phosphatidylinositol 4,5-bisphosphate-mediated membrane permeabilization". Science Advances 4 (7): eaat0979. July 2018. doi:10.1126/sciadv.aat0979. PMID 30050988. Bibcode: 2018SciA....4..979J. 
  28. ↑ "Differential Interaction of Antimicrobial Peptides with Lipid Structures Studied by Coarse-Grained Molecular Dynamics Simulations". Molecules 22 (10): 1775. October 2017. doi:10.3390/molecules22101775. PMID 29053635. 
  29. ↑ "Designing improved active peptides for therapeutic approaches against infectious diseases". Biotechnology Advances 36 (2): 415–429. 9 January 2018. doi:10.1016/j.biotechadv.2018.01.004. PMID 29330093. 
  30. ↑ "New insights on Drosophila antimicrobial peptide function in host defense and beyond". Current Opinion in Immunology 62: 22–30. February 2020. doi:10.1016/j.coi.2019.11.008. PMID 31835066. 
  31. ↑ "Antimicrobial host defence peptides: functions and clinical potential". Nature Reviews. Drug Discovery 19 (5): 311–332. May 2020. doi:10.1038/s41573-019-0058-8. PMID 32107480. https://www.pure.ed.ac.uk/ws/files/138110044/Mookherjee_Anderson_Haagsman_Davidson_NRDD_2020_accepted.pdf. 
  32. ↑ 32.0 32.1 "Studies on anticancer activities of antimicrobial peptides". Biochimica et Biophysica Acta (BBA) - Biomembranes 1778 (2): 357–375. February 2008. doi:10.1016/j.bbamem.2007.11.008. PMID 18078805. 
  33. ↑ "The antimicrobial peptide defensin cooperates with tumour necrosis factor to drive tumour cell death in Drosophila". eLife 8. July 2019. doi:10.7554/eLife.45061. PMID 31358113. 
  34. ↑ "The insect antimicrobial peptide cecropin A disrupts uropathogenic Escherichia coli biofilms". npj Biofilms and Microbiomes 6 (1): 6. February 2020. doi:10.1038/s41522-020-0116-3. PMID 32051417. 
  35. ↑ "Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance". Journal of Applied Microbiology 113 (4): 723–736. October 2012. doi:10.1111/j.1365-2672.2012.05338.x. PMID 22583565. 
  36. ↑ "A novel antimicrobial peptide derived from fish goose type lysozyme disrupts the membrane of Salmonella enterica". Molecular Immunology 68 (2 Pt B): 421–433. December 2015. doi:10.1016/j.molimm.2015.10.001. PMID 26477736. 
  37. ↑ "Bactericidal activity of fish galectin 4 derived membrane-binding peptide tagged with oligotryptophan". Developmental and Comparative Immunology 71: 37–48. June 2017. doi:10.1016/j.dci.2017.01.019. PMID 28126555. 
  38. ↑ "Macrobrachium rosenbergii mannose binding lectin: synthesis of MrMBL-N20 and MrMBL-C16 peptides and their antimicrobial characterization, bioinformatics and relative gene expression analysis". Fish & Shellfish Immunology 43 (2): 364–374. April 2015. doi:10.1016/j.fsi.2014.12.036. PMID 25575476. 
  39. ↑ "In Spiny anteater's milk could be an alternative to antibiotics" (in en). Chennai, India: Kasturi & Sons Ltd.. 24 April 2019. https://www.thehindubusinessline.com/news/variety/in-spiny-anteaters-milk-could-be-an-alternative-to-antibiotics/article26934316.ece. 
  40. ↑ "Egg-laying mammal's milk may help for novel antibiotics" (in en). Press Trust of India. India: The Printers Mysore. 25 April 2019. https://www.deccanherald.com/science-and-environment/egg-laying-mammals-milk-may-help-for-novel-antibiotics-730594.html. 
  41. ↑ 41.0 41.1 "Control of cell selectivity of antimicrobial peptides". Biochimica et Biophysica Acta (BBA) - Biomembranes 1788 (8): 1687–1692. August 2009. doi:10.1016/j.bbamem.2008.09.013. PMID 18952049. 
  42. ↑ "High concentration of beta-defensin-2 in oral squamous cell carcinoma". Anticancer Research 22 (4): 2103–2107. 2002. PMID 12174890. 
  43. ↑ "Surrounding cells affect the gene expression pattern of human beta-defensins in squamous cell carcinoma in vitro". Anticancer Research 34 (11): 6443–6449. November 2014. PMID 25368244. http://ar.iiarjournals.org/content/34/11/6443.long. Retrieved 7 February 2019. 
  44. ↑ 44.0 44.1 "Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies". Nature Biotechnology 24 (12): 1551–1557. December 2006. doi:10.1038/nbt1267. PMID 17160061. 
  45. ↑ 45.0 45.1 "Antimicrobial peptides of multicellular organisms". Nature 415 (6870): 389–395. January 2002. doi:10.1038/415389a. PMID 11807545. Bibcode: 2002Natur.415..389Z. 
  46. ↑ 46.0 46.1 "Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2". Biochemistry 34 (10): 3423–3429. March 1995. doi:10.1021/bi00010a034. PMID 7533538. 
  47. ↑ "Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp". International Journal of Antimicrobial Agents 32 (2): 130–138. August 2008. doi:10.1016/j.ijantimicag.2008.04.003. PMID 18586467. 
  48. ↑ "Molecular evolution of animal antimicrobial peptides: widespread moderate positive selection". Journal of Evolutionary Biology 18 (6): 1387–1394. November 2005. doi:10.1111/j.1420-9101.2005.00925.x. PMID 16313451. 
  49. ↑ "Interaction of an artificial antimicrobial peptide with lipid membranes". Biochimica et Biophysica Acta (BBA) - Biomembranes 1788 (2): 333–344. February 2009. doi:10.1016/j.bbamem.2008.10.005. PMID 19013127. 
  50. ↑ "Molecular Imaging and Orientational Changes of Antimicrobial Peptides in Membranes". Peptides for Youth. Advances in Experimental Medicine and Biology. 611. 2009. pp. 313–315. doi:10.1007/978-0-387-73657-0_140. ISBN 978-0-387-73656-3. Bibcode: 2009peyo.book..313L. 
  51. ↑ "Effects of Pro --> peptoid residue substitution on cell selectivity and mechanism of antibacterial action of tritrpticin-amide antimicrobial peptide". Biochemistry 45 (43): 13007–13017. October 2006. doi:10.1021/bi060487+. PMID 17059217. 
  52. ↑ "Antimicrobial peptides for detection of bacteria in biosensor assays". Analytical Chemistry 77 (19): 6504–6508. October 2005. doi:10.1021/ac050639r. PMID 16194120. 
  53. ↑ 53.0 53.1 "Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides". The Journal of Biological Chemistry 274 (13): 8405–8410. March 1999. doi:10.1074/jbc.274.13.8405. PMID 10085071. 
  54. ↑ "Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides". Infection and Immunity 72 (12): 7107–7114. December 2004. doi:10.1128/IAI.72.12.7107-7114.2004. PMID 15557634. 
  55. ↑ "Role of YadA in resistance of Yersinia enterocolitica to phagocytosis by human polymorphonuclear leukocytes". Infection and Immunity 62 (4): 1275–1281. April 1994. doi:10.1128/IAI.62.4.1275-1281.1994. PMID 8132334. 
  56. ↑ "Sap transporter mediated import and subsequent degradation of antimicrobial peptides in Haemophilus". PLOS Pathogens 7 (11): e1002360. November 2011. doi:10.1371/journal.ppat.1002360. PMID 22072973. 
  57. ↑ "Multidrug efflux pumps of gram-negative bacteria". Journal of Bacteriology 178 (20): 5853–5859. October 1996. doi:10.1128/jb.178.20.5853-5859.1996. PMID 8830678. 
  58. ↑ "The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases". The Journal of Biological Chemistry 271 (17): 10079–10086. April 1996. doi:10.1074/jbc.271.17.10079. PMID 8626565. 
  59. ↑ "Molecular characterization and functional analysis of outer membrane vesicles from the antarctic bacterium Pseudomonas syringae suggest a possible response to environmental conditions". Journal of Proteome Research 13 (3): 1345–1358. March 2014. doi:10.1021/pr4009223. PMID 24437924. 
  60. ↑ "Bis-(3'-5')-cyclic dimeric GMP regulates antimicrobial peptide resistance in Pseudomonas aeruginosa". Antimicrobial Agents and Chemotherapy 57 (5): 2066–2075. May 2013. doi:10.1128/AAC.02499-12. PMID 23403434. 
  61. ↑ "Therapeutic antimicrobial peptides may compromise natural immunity". Biology Letters 8 (3): 416–418. June 2012. doi:10.1098/rsbl.2011.1203. PMID 22279153. 
  62. ↑ "Antimicrobial peptides". Pharmaceuticals 6 (12): 1543–1575. November 2013. doi:10.3390/ph6121543. PMID 24287494. 
  63. ↑ "Chapter 7. Building a Trojan Horse: Siderophore-Drug Conjugates for the Treatment of Infectious Diseases". Essential Metals in Medicine:Therapeutic Use and Toxicity of Metal Ions in the Clinic. 19. Berlin: de Gruyter GmbH. 2019. 181–202. doi:10.1515/9783110527872-013. ISBN 978-3-11-052691-2. 
  64. ↑ "Insect antimicrobial peptides OPM". Orientations of Proteins in Membranes database (OPM). http://opm.phar.umich.edu/families.php?superfamily=160. 
  65. ↑ "Differential activity of lytic α-helical peptides on lactobacilli and lactobacilli-derived liposomes". Biochimica et Biophysica Acta (BBA) - Biomembranes 1861 (6): 1069–1077. June 2019. doi:10.1016/j.bbamem.2019.03.004. PMID 30878358. 
  66. ↑ "Amphibian antimicrobial peptides". Orientations of Proteins in Membranes database (OPM). http://opm.phar.umich.edu/families.php?superfamily=309. 
  67. ↑ "Structure-function analysis of Avian β-defensin-6 and β-defensin-12: role of charge and disulfide bridges". BMC Microbiology 16 (1): 210. September 2016. doi:10.1186/s12866-016-0828-y. PMID 27613063. 
  68. ↑ "Synthetic Mimics of Antimicrobial Peptides: A New Wave of Antibiotics". Department of Chemistry. University of Georgia. 9 February 2012. http://www.chem.uga.edu/seminars/4702-synthetic-mimics-antimicrobial-peptides-new-wave-antibiotics. 
  69. ↑ "Role of Cationic Side Chains in the Antimicrobial Activity of C18G". Molecules 23 (2): 329. February 2018. doi:10.3390/molecules23020329. PMID 29401708. 
  70. ↑ "Biomedical applications of nisin". Journal of Applied Microbiology 120 (6): 1449–1465. June 2016. doi:10.1111/jam.13033. PMID 26678028. 
  71. ↑ "A large-scale structural classification of antimicrobial peptides". BioMed Research International 2015: 475062. February 2015. doi:10.1155/2015/475062. PMID 26000295. 
  72. ↑ "CAMP: Collection of sequences and structures of antimicrobial peptides". Nucleic Acids Research 42 (Database issue): D1154–D1158. January 2014. doi:10.1093/nar/gkt1157. PMID 24265220. 
  73. ↑ "DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides". Nucleic Acids Research 50 (Database issue): D488–D496. January 2022. doi:10.1093/nar/gkab651. PMID 34390348. 
  74. ↑ "Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity". PLOS ONE 7 (10): e45012. 8 October 2012. doi:10.1371/journal.pone.0045012. PMID 23056189. Bibcode: 2012PLoSO...745012M. 
  75. ↑ "PeptideLocator: prediction of bioactive peptides in protein sequences". Bioinformatics 29 (9): 1120–1126. May 2013. doi:10.1093/bioinformatics/btt103. PMID 23505299. 
  76. ↑ "modlAMP: Python for antimicrobial peptides". Bioinformatics 33 (17): 2753–2755. September 2017. doi:10.1093/bioinformatics/btx285. PMID 28472272. 
  77. ↑ "Prediction of Antimicrobial Potential of a Chemically Modified Peptide From Its Tertiary Structure". Frontiers in Microbiology 9: 2551. 26 October 2018. doi:10.3389/fmicb.2018.02551. PMID 30416494. 
  78. ↑ "In Silico Approach for Prediction of Antifungal Peptides". Frontiers in Microbiology 9: 323. 26 February 2018. doi:10.3389/fmicb.2018.00323. PMID 29535692. 
  79. ↑ "Prediction of Antitubercular Peptides From Sequence Information Using Ensemble Classifier and Hybrid Features". Frontiers in Pharmacology 9: 954. 26 August 2018. doi:10.3389/fphar.2018.00954. PMID 30210341. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Antimicrobial_peptides&oldid=3504601#Antimicrobial_Peptide_Database"